Research Topics
| Anthony J LemboSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Irritable bowel syndrome: toward an understanding of severityAnthony Lembo
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Clin Gastroenterol Hepatol 3:717-25. 2005..However, studies have not been adequately designed to determine the relative values of these factors in IBS severity...- Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorderAnthony Lembo
Department of Gastroenterology, Beth Israel Deaconess Hospital, Boston, Massachusetts 02215, USA
Drugs 63:1895-905. 2003..Prescribing restrictions and the risk-management programme implemented as required by the US FDA is reviewed along with a summary of the studies to be performed after reintroduction of alosetron to monitor safety... - A 54-year-old woman with constipation-predominant irritable bowel syndromeAnthony J Lembo
Harvard Medical School, Boston, Mass, USA
JAMA 295:925-33. 2006 
A treatment trial of acupuncture in IBS patientsAnthony J Lembo
The Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rabb Rose 1, Boston, MA 02215, USA
Am J Gastroenterol 104:1489-97. 2009..This study aimed to compare the effects of true and sham acupuncture in relieving symptoms of irritable bowel syndrome (IBS)...- Chronic constipationAnthony Lembo
Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
N Engl J Med 349:1360-8. 2003 
Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, studyA J Lembo
Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center BIDMC, Harvard Medical School, Boston, MA 02215, USA
Aliment Pharmacol Ther 31:979-90. 2010..Renzapride, a 5-hydroxytryptamine type-4 (5-HT(4)) receptor agonist and 5-HT(3) receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (IBS-C)...- Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipationAnthony J Lembo
Division of Gastroenterology, Harvard Medical School, 330 Brookline Ave, DA 501, Boston, MA, USA
Dig Dis Sci 56:2639-45. 2011..Lubiprostone helps relieve constipation in short-term 4-week studies. There are limited data on long-term pharmacological treatment with lubiprostone for chronic idiopathic constipation... - Current gut-directed therapies for irritable bowel syndromeHoward Y Chang
Beth Israel Deaconess Medical Center Harvard University Medical School, 330 Brookline Avenue, Dana 501, Boston, MA 02215, USA
Curr Treat Options Gastroenterol 9:314-23. 2006..However, alosetron is available under a restricted license because of concerns for ischemic colitis and severe constipation necessitating colectomy. Clonidine may be helpful in alleviating global symptoms for D-IBS patients... - Irritable bowel syndrome medications side effects surveyAnthony Lembo
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
J Clin Gastroenterol 38:776-81. 2004..This study was conducted to determine the frequency and severity of side effects (SEs) experienced during treatment with standard medications used to treat patients with irritable bowel syndrome (IBS) with constipation (IBS-C)... - Efficacy of linaclotide for patients with chronic constipationAnthony J Lembo
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 138:886-95.e1. 2010..We assessed the safety and efficacy of a range of linaclotide doses in patients with chronic constipation... - Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyWilliam D Chey
Division of Gastroenterology, Department of Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA
Am J Gastroenterol 107:1702-12. 2012..The objective of this trial was to determine the effi cacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks... - Two randomized trials of linaclotide for chronic constipationAnthony J Lembo
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
N Engl J Med 365:527-36. 2011..Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation... - Components of placebo effect: randomised controlled trial in patients with irritable bowel syndromeTed J Kaptchuk
Osher Research Center, Harvard Medical School, 401 Park Drive, Boston, MA 02215, USA
BMJ 336:999-1003. 2008..To assess the relative magnitude of these components... - Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipationJeffrey M Johnston
Ironwood Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
Gastroenterology 139:1877-1886.e2. 2010..We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C... - "Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trialTed J Kaptchuk
Osher Research Center, Harvard Medical School, 401 Park Drive, Boston, MA 02215, USA
Cult Med Psychiatry 33:382-411. 2009..g. expectancy, hope, conditioning, anxiety reduction, report bias, symbolic work, narrative and embodiment--provides an inadequate model to explain its salubrious benefits... - Adequate relief in a treatment trial with IBS patients: a prospective assessmentMaria C F Passos
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Am J Gastroenterol 104:912-9. 2009.... - Placebos without deception: a randomized controlled trial in irritable bowel syndromeTed J Kaptchuk
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 5:e15591. 2010..We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS)... - Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patientsSiu Ping Chin Feman
Osher Institute, Harvard Medical School, Boston, MA 02215, United States
Contemp Clin Trials 29:241-51. 2008..The iterative use of the efficacy index during a recruitment campaign may be helpful to calibrate and focus on the most effective recruitment methods... - Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trialsAnthony J Lembo
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Clin Gastroenterol Hepatol 2:675-82. 2004..No cases of ischemic colitis were reported. CONCLUSIONS: Alosetron effectively manages bowel urgency and improves global symptoms in women with severe chronic D-IBS... - Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndromeKathryn T Hall
Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 7:e48135. 2012..These data support our hypothesis that the COMT val158met polymorphism is a potential biomarker of placebo response... - Pilot study on the effect of linaclotide in patients with chronic constipationJeffrey M Johnston
Ironwood Pharmaceuticals, Inc, 320 Bent Street, Cambridge, MA, USA
Am J Gastroenterol 104:125-32. 2009..In Phase 1 studies in healthy human volunteers, linaclotide was well-tolerated, increased bowel movement frequency, and loosened stool consistency... - Investigating placebo effects in irritable bowel syndrome: a novel research designLisa A Conboy
Osher Institute, Division for Research and Education in Complementary and Integrative Therapies, Harvard Medical School, 401 Park Drive, Suite 22A, Boston, MA 02115, USA
Contemp Clin Trials 27:123-34. 2006..quot; The trial also uses an innovative combination of quantitative and qualitative methods... - Patient and practitioner influences on the placebo effect in irritable bowel syndromeJohn M Kelley
Psychology Department, Endicott College, 376 Hale Street, Beverly, MA 01915, USA
Psychosom Med 71:789-97. 2009..To determine whether placebo responses can be explained by characteristics of the patient, the practitioner, or their interpersonal interaction... - Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationshipLisa Ann Conboy
Harvard Medical School, Osher Research Center, Boston, MA United States
Soc Sci Med 70:479-84. 2010..These results converge with the results of the parent trial, implicating the importance of the social world in healing... - Peripheral opioids for functional GI disease: a reappraisalAnthony Lembo
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Dig Dis 24:91-8. 2006..Further studies are on hold presumably due to lack of efficacy in subsequent studies. However, clinical studies are underway for newer kappa opioid agonists such as asimadoline and ADL 10-0101... - Psychiatric disorder, irritable bowel syndrome, and extra-intestinal symptoms in a population-based sample of twinsAnthony J Lembo
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Am J Gastroenterol 104:686-94. 2009.... - Visceral hypersensitivity in noncardiac chest painAnthony J Lembo
Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Hospital, Dana 501, 330 Brookline Avenue, Boston, MA 02215, USA
Gastroenterol Clin North Am 33:55-60. 2004..The processing of visceral information and possibly the development of central sensitization may be important in NCCP, although the pathophysiology of NCCPremains poorly understood... - Spasm, nutcracker, and IEM: real or manometry findings?Thomas Konturek
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
J Clin Gastroenterol 42:647-51. 2008..Likewise, as no subjects had >20% simultaneous contractions (though a considerable number, 4%, had 10% simultaneous contractions), esophageal spasm was defined at the >20% mark... - Endoscopic full-thickness plication for the treatment of GERD: a multicenter trialDouglas Pleskow
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Gastrointest Endosc 59:163-71. 2004..CONCLUSIONS: In this study, a single full-thickness plication placed at the gastroesophageal junction reduced symptoms, medication use, and esophageal acid exposure associated with GERD... - Review of tegaserod in the treatment of irritable bowel syndromeSonal Patel
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Expert Opin Pharmacother 5:2369-79. 2004..Tegaserod was well-tolerated. The most common adverse reaction in clinical trials was diarrhoea, which was usually temporary and mild, although severe diarrhoea requiring hospitalisation has been rarely (< 1%) reported... - Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trialDouglas Pleskow
Division of Gastroenterology, Department of Medicne, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Gastrointest Endosc 61:643-9. 2005..It reduces reflux symptoms and antisecretory medication use over at least a 1-year period... - Management of Crohn's disease in adultsGary R Lichtenstein
Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Am J Gastroenterol 104:465-83; quiz 464, 484. 2009..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time... - Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesisBrian Hyett
Division of Gastroenterology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
Gastroenterology 137:445-52. 2009..The aim of this study was to evaluate the prognostic value of gastric emptying studies on the morbidity associated with diabetic gastroparesis... - A novel endoscopic full-thickness plicator for the treatment of GERD: A pilot studyRam Chuttani
Harvard Medical School, Boston, Massachusetts, USA
Gastrointest Endosc 58:770-6. 2003..CONCLUSIONS: Endoscopic full-thickness plication is feasible, safe and, in this pilot study, appeared to reduce symptoms and medication use associated with GERD... - Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trialJohn F Johanson
University of Illinois College of Medicine, Rockford, IL, USA
Clin Gastroenterol Hepatol 2:796-805. 2004..CONCLUSIONS: Over 12 weeks, tegaserod treatment produced significant improvements in chronic constipation symptoms and was also safe and well tolerated... - Neurotrophin-3 improves functional constipationHenry P Parkman
Temple University Hospital, Philadelphia, Pennsylvania 19140, USA
Am J Gastroenterol 98:1338-47. 2003..CONCLUSIONS: NT-3, administered TTW, increased stool frequency, enhanced colon transit, and improved symptoms of chronic constipation. NT-3 seems to be a novel, safe, and effective agent for the treatment of functional constipation...